Learn more

GREEN CROSS LAB CELL CORP

Overview
  • Total Patents
    54
  • GoodIP Patent Rank
    28,207
  • Filing trend
    ⇩ 7.0%
About

GREEN CROSS LAB CELL CORP has a total of 54 patent applications. It decreased the IP activity by 7.0%. Its first patent ever was published in 2012. It filed its patents most often in Republic of Korea, WIPO (World Intellectual Property Organization) and Australia. Its main competitors in its focus markets pharmaceuticals, biotechnology and basic materials chemistry are SHANGHAI CLEAR FLUID BIOMEDICAL SCIENCE CO LTD, CROWN IN THE RIGHT OF THE QUEE and GUANGDONG FIRST CONDOR BIOTECHNOLOGY CO LTD.

Patent filings per year

Chart showing GREEN CROSS LAB CELL CORPs patent filings per year from 1900 to 2020

Top inventors

# Name Total Patents
#1 Hwang Yu Kyeong 39
#2 Min Bokyung 17
#3 Kim Hyojin 14
#4 Kim Hyun Ah 14
#5 Choi Hana 13
#6 Jung Mi Young 12
#7 Cho Sung Yoo 11
#8 Lim Ho Yong 11
#9 Won Sung Yong 10
#10 Gwon Su Hyun 10

Latest patents

Publication Filing date Title
US2020399397A1 Anti-her2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
WO2020101361A1 Method for culturing cord blood-derived natural killer cells using transformed t-cells
KR20200056333A Method for culturing natural killer cells derived from cord bloods with genetically engineered t cells
WO2019182392A1 Method for producing natural killer cells
KR20190111804A Method for Preparing NK Cell
AU2018370195A1 Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
KR20200030337A Pharmaceutical combinations for treating tumor comprising anti-cd19 antibody and natural killer cell
KR20190141511A New peptide, chemeric antigen receptor and immune cell expressing the same
AU2018271755A1 Method for culturing natural killer cell, using transformed T cell
EP3567049A2 Chimeric antigen receptor and natural killer cells expressing same
KR20190075594A Novel drug delivery composition and pharmaceutical composition for treating gm1 gangliosidosis comprising the same
KR20190000569A Transformed stem cell expressing glb1 gene and pharmaceutical composition for treating gm1 gangliosidosis comprising same
KR20180085796A Medium composition for cryopreservation of cells and uses thereof
KR20170007707A Method for Preparation of Natural Killer Cells Using T Cells
KR20180056853A Composition for improving skin conditions comprising cord blood plasma
WO2017003153A1 Method for producing natural killer cells from cord blood monocytes or cells derived therefrom
KR20160008987A Intranasal composition comprising stem cells expressing a subtance for treating brain-nervous system diseases
KR20160066837A Efficient Method for Preparing of Stable Natural Killer Cells
KR20160063114A Method for Preparation of Natural Killer Cells Using T Cells
KR20150115304A Method for preparation of insulin secreting cells differentiated from mesenchymal stem cells speroid and use thereof